A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Phase 1 Completed 84 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.

Timeline

Start: 2015-09
Primary completion: 2015-11
Completion: 2015-12

Publications

Gomez EV, Bishop JL, Jackson K, Muram TM, Phillips D. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. BioDrugs. 2017 Dec;31(6):545-554. doi: 10.1007/s40259-017-0249-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Boostrix	Vaccine	—	Intramuscular
Subject	Ixekizumab	Monoclonal antibody	80 mg	Subcutaneous
Subject	Pneumovax 23	Vaccine	—	Intramuscular

Indications

No indication recorded.